## CITATION REPORT List of articles citing

Absorption, disposition, metabolism and excretion of [C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats

DOI: 10.1080/00498254.2018.1449269 Xenobiotica, 2019, 49, 463-473.

Source: https://exaly.com/paper-pdf/74854077/citation-report.pdf

Version: 2024-04-05

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 603-613	18.8	20
7	Whata in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 317, G640-G650	5.1	5
6	What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. <i>Diabetes, Obesity and Metabolism,</i> <b>2019</b> , 21 Suppl 2, 43-52	6.7	33
5	Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation. Journal of Neurogastroenterology and Motility, <b>2019</b> , 25, 332-333	4.4	
4	Pharmacological Treatments for Constipation and Opioid-Induced Constipation. 2021,		
3	SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy via the JNK and p38 Pathway. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 598353	5.6	5
2	Emerging therapies in the management of Irritable Bowel Syndrome (IBS) Expert Opinion on Emerging Drugs, 2022,	3.7	
1	In-vivo imaging of a mouse by detecting bremsstrahlung X-rays from 14C using a La-GPS imaging system. <i>Journal of Nuclear Science and Technology</i> , 1-12	1	